The Jan. 14, 2016, joint meeting of the NCATS Advisory Council and the Cures Acceleration Network Review Board featured the following meeting materials.
Presentations
- NCATS Director’s Report (PDF - 2MB) - Christopher P. Austin, M.D., director, NCATS
- CAN Review Board Update (PDF - 169KB) - Freda C. Lewis-Hall, M.D., chief medical officer, Pfizer
- NCATS Strategic Planning Update (PDF - 347KB) - Dorit Zuk, Ph.D., director, Office of Policy, Communications and Strategic Alliances, NCATS
- Concept Clearance: Clinical and Translational Science Data Metrics Coordinating Center (PDF - 133KB) - Petra Kaufmann, M.D., M.Sc., director, Office of Rare Diseases Research and the Division of Clinical Innovation, NCATS
- Concept Clearance: Collaborative Innovation Pilot Projects for the CTSA Program (PDF - 161KB) - Petra Kaufmann, M.D., M.Sc., director, Office of Rare Diseases Research and the Division of Clinical Innovation, NCATS
- NCATS Partnerships with NIH Common Fund: Overview and Extracellular RNA (ExRNA) Communication Program (PDF - 1MB) - Danilo A. Tagle, Ph.D., associate director for special initiatives, NCATS
- Undiagnosed Diseases Network (UDN) Program (PDF - 2MB) - Carson R. Loomis, Ph.D., senior advisor to the director, NCATS; and David J. Eckstein, Ph.D., senior health scientist administrator, Office of Rare Diseases Research, NCATS
- Update from the CTSA and ORDR Programs (PDF - 2MB) - Petra Kaufmann, M.D., M.Sc., director, Office of Rare Diseases Research and the Division of Clinical Innovation, NCATS
Additional Meeting Information
- Agenda (PDF - 80KB)
- Videocast
- Minutes (PDF - 220KB)
- Federal Register Notice
- Concept Clearances